Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on the day's biggest business stories
Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Moderna CEO Stéphane Bancel. Photo: Adam Glanzman/Bloomberg via Getty Images
Moderna's CEO Stéphane Bancel tells Axios the company's coronavirus vaccine made it to market in near-record time thanks in part to a unique digital foundation.
The big picture: Moderna is far smaller than many of its pharma competitors, but it made one of the first authorized COVID-19 vaccines. But the company still needs to adapt to a mutating virus — and come up with its next blockbuster product.
What they're saying: While Moderna's SARS-CoV-2 vaccine is already beginning to make a dent in the pandemic, the shifting virus still poses a major challenge to the company and all of humanity, Bancel told Axios in an interview.
- "I think the world does not understand what's coming ahead of us," says Bancel. "I don't think we're out of the woods at all on this pandemic."
Background: That Moderna — which is barely more than a decade old and is far smaller than most of its competitors — was able to bring its vaccine to market in less than a year is a testament to the flexibility of its mRNA platform and its early embrace of digital technology and machine learning.
- At bigger companies where Bancel worked in the past, "I'd spend days trying to figure out what was the truth, because you'd have different data for the same thing," he says.
- "We try to be a company where all the data flows and where there's only one system, one truth."
What's next: The emergence of coronavirus variants that may render vaccines less effective has Moderna preparing booster shots — something that's easier to do with the mRNA platform.
- The COVID-19 vaccines made by Moderna and other companies could become a recurring product, just as the seasonal flu shot is now.
What to watch: How quickly Moderna can continue to scale up manufacturing to meet demand, a function that Bancel says is limited by regulatory requirements and sheer technical complexity.
- Is there much that can be done "in the short term?" he asks. "Not really."
Go deeper: Moderna says vaccine appears to protect against new COVID-19 variants